1 reply to this topic

[theone]

The authors inhibited the acsd-1 gene, which encodes the equivalent of ACMSD in nematodes. This inhibition did increase NAD⁺ levels.

 

 

The authors therefore developed chemical inhibitors of ACMSD, and tested whether these inhibitors could improve outcomes in mouse models of two ageing-related diseases: diet-induced fatty liver disease and acute kidney injury.

 

 

Katsyuba and colleagues’ data confirmed the potential for therapeutic NAD⁺ augmentation — treatment with their inhibitors protected against disease in these models. The results also suggest that increases in the de novo NAD⁺ synthesis pathway alone are sufficiently robust to ameliorate liver and kidney diseases associated with low NAD⁺ levels.

 

 

https://www.nature.c...586-018-07088-4

 

[albedo]

Good information. I am following this team (Auwerx) since some time already and this looks great progress. See also:

https://www.longecit...ndpost&p=847777